WO2012172339A3 - Traitement de l'arthrite inflammatoire - Google Patents

Traitement de l'arthrite inflammatoire Download PDF

Info

Publication number
WO2012172339A3
WO2012172339A3 PCT/GB2012/051348 GB2012051348W WO2012172339A3 WO 2012172339 A3 WO2012172339 A3 WO 2012172339A3 GB 2012051348 W GB2012051348 W GB 2012051348W WO 2012172339 A3 WO2012172339 A3 WO 2012172339A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine receptor
treating inflammatory
inflammatory arthritis
ccr1
ccr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2012/051348
Other languages
English (en)
Other versions
WO2012172339A2 (fr
Inventor
Ola Winqvist
Graham Cotton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITH Immune Therapy Holdings AB
Original Assignee
ITH Immune Therapy Holdings AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITH Immune Therapy Holdings AB filed Critical ITH Immune Therapy Holdings AB
Publication of WO2012172339A2 publication Critical patent/WO2012172339A2/fr
Publication of WO2012172339A3 publication Critical patent/WO2012172339A3/fr
Priority to US14/105,628 priority Critical patent/US9726666B2/en
Anticipated expiration legal-status Critical
Priority to US15/629,691 priority patent/US10451620B2/en
Priority to US15/629,700 priority patent/US10422800B2/en
Priority to US15/629,713 priority patent/US10408832B2/en
Priority to US15/629,697 priority patent/US10502736B2/en
Priority to US15/629,708 priority patent/US10401357B2/en
Priority to US15/629,705 priority patent/US10429385B2/en
Priority to US16/537,224 priority patent/US20190361020A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode de traitement de l'arthrite inflammatoire consistant à appliquer du sang périphérique d'un patient ou sujet sur une colonne d'aphérèse chargée d'un support solide comprenant un ou plusieurs réactifs de liaison pouvant se lier spécifiquement à un récepteur de chimiokines, éventuellement le récepteur de chimiokines CCR2, CCR1, CCR3 ou CCR5, immobilisé directement ou indirectement sur le support, éliminant ainsi au moins un récepteur de chimiokines, éventuellement des cellules exprimant le CCR2, le CCR1, le CCR3 et le CCR5 à partir du sang périphérique du patient ou sujet. L'invention concerne également diverses méthodes de diagnostic compagnon ainsi que des réactifs de liaison utiles.
PCT/GB2012/051348 2011-06-13 2012-06-13 Traitement de l'arthrite inflammatoire Ceased WO2012172339A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/105,628 US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases
US15/629,705 US10429385B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with sepsis
US15/629,691 US10451620B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with metabolic syndrome
US15/629,708 US10401357B2 (en) 2011-06-13 2017-06-21 Treating cancer
US15/629,697 US10502736B2 (en) 2011-06-13 2017-06-21 Treating multiple sclerosis
US15/629,700 US10422800B2 (en) 2011-06-13 2017-06-21 Treating respiratory conditions
US15/629,713 US10408832B2 (en) 2011-06-13 2017-06-21 Treating mental disorders
US16/537,224 US20190361020A1 (en) 2011-06-13 2019-08-09 Treating respiratory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496288P 2011-06-13 2011-06-13
US61/496,288 2011-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051351 Continuation-In-Part WO2012172341A2 (fr) 2011-06-13 2012-06-13 Traitement du cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2012/051349 Continuation-In-Part WO2013041833A1 (fr) 2011-06-13 2012-06-13 Traitement d'états associés à un syndrome métabolique
US14/105,628 Continuation-In-Part US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases

Publications (2)

Publication Number Publication Date
WO2012172339A2 WO2012172339A2 (fr) 2012-12-20
WO2012172339A3 true WO2012172339A3 (fr) 2013-03-07

Family

ID=46317434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051348 Ceased WO2012172339A2 (fr) 2011-06-13 2012-06-13 Traitement de l'arthrite inflammatoire

Country Status (1)

Country Link
WO (1) WO2012172339A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3108515B1 (fr) * 2020-03-26 2022-03-25 Ct Hospitalier Universitaire Toulouse Colonne d’aphérèse pour le traitement de la polyarthrite rhumatoïde

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2007133147A1 (fr) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Procédé et moyens pour traiter les maladies inflammatoires chroniques de l'intestin
WO2010021697A2 (fr) * 2008-08-18 2010-02-25 Pfizer Inc. Anticorps anti-ccr2
WO2010029317A2 (fr) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Traitement d’états inflammatoires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537362A (ja) 1999-02-22 2002-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ビオチン化ケモカイン抗体複合体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2007133147A1 (fr) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Procédé et moyens pour traiter les maladies inflammatoires chroniques de l'intestin
WO2010021697A2 (fr) * 2008-08-18 2010-02-25 Pfizer Inc. Anticorps anti-ccr2
WO2010029317A2 (fr) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Traitement d’états inflammatoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
L TYLASKA: "CCR2 REGULATES THE LEVEL OF MCP-1/CCL2 IN VITRO AND AT INFLAMMATORY SITES AND CONTROLS T CELL ACTIVATION IN RESPONSE TO ALLOANTIGEN", CYTOKINE, vol. 18, no. 4, 1 May 2002 (2002-05-01), pages 184 - 190, XP055035952, ISSN: 1043-4666, DOI: 10.1006/cyto.2002.1031 *
M. N. SARAFI ET AL: "Murine Monocyte Chemoattractant Protein (MCP)-5: A Novel CC Chemokine That Is a Structural and Functional Homologue of Human MCP-1", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 1, 1 January 1997 (1997-01-01), pages 99 - 110, XP055035882, ISSN: 0022-1007, DOI: 10.1084/jem.185.1.99 *
TAKUJI IWAMOTO ET AL: "Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients", FEBS JOURNAL, vol. 275, no. 18, 1 September 2008 (2008-09-01), pages 4448 - 4455, XP055036303, ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2008.06580.x *
VERGUNST CLARISSA E ET AL: "Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial", ARTHRITIS & RHEUMATISM, JOHN WILEY & SONS, INC, US, vol. 58, no. 7, 1 July 2008 (2008-07-01), pages 1931 - 1939, XP002676223, ISSN: 0004-3591, DOI: 10.1002/ART.23591 *

Also Published As

Publication number Publication date
WO2012172339A2 (fr) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012172341A3 (fr) Traitement du cancer
Allen et al. Biological and psychological markers of stress in humans: Focus on the Trier Social Stress Test
WO2010029317A8 (fr) Traitement d'états inflammatoires
WO2014011536A3 (fr) Dispositifs de collecte d'échantillons biologiques et procédés de production et d'utilisation associés
WO2013013025A3 (fr) Anticorps anti-cxcr4 et leurs procédés d'utilisation
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EP2374871A4 (fr) Cellules souches pluripotentes, procédé pour la préparation de celles-ci et utilisations de celles-ci
EP2244663A4 (fr) Dispositif, système et procédé d'élimination de caillots sanguins
HUP1200205A2 (en) Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
WO2011008520A3 (fr) Procédés et dispositif de test d'analyte pour calculer une thérapie par insuline basale
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
WO2010135603A3 (fr) Méthode de dépistage, de diagnostic et de pronostic du cancer
AR080505A1 (es) Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores
WO2010025321A3 (fr) Procédé de traitement de patients souffrant de sclérose en plaques avec des anticorps anti-il2r
WO2012064834A3 (fr) Procédés de régénération d'organe
JP2016501013A5 (fr)
WO2011095501A8 (fr) Procédé de réduction de complexité
WO2014093051A3 (fr) Cellules souches cardiaques et leurs procédés d'identification et d'utilisation
EA033141B1 (ru) Сшитые кристаллы белка а и их применение
WO2011117357A3 (fr) Pile flexible à combustible biologique, dispositif et procédé associés
EP2626276A4 (fr) Dispositif de support pour colonne de direction et son procédé d'assemblage
WO2010009129A3 (fr) Méthodes de traitement de maladies auto-immunes utilisant des anticorps cd4
WO2008157222A3 (fr) Dispositif et procédés pour introduire un cathéter dans un disque intervertébral
WO2012172337A3 (fr) Traitement de maladie cardiovasculaire
WO2012172336A3 (fr) Traitement de maladies inflammatoires de la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727913

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727913

Country of ref document: EP

Kind code of ref document: A2